SCM
CUE icon

Silverarc Capital Management’s Cue Biopharma CUE Stock Holding History

Silverarc Capital Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,447
Closed -$1.47M – 86
2023
Q2 		$1.47M Buy
13,447
+3,238
+32% +$381K 0.46% 50
2023
Q1 		$1.09M Hold
10,209
– – 0.45% 57
2022
Q4 		$873K Buy
+10,209
New +$934K 0.25% 71

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Silverarc Capital Management's CUE Position: Q3 2023 in Review

Silverarc Capital Management sold out of Cue Biopharma (CUE) in Q3 2023, closing a stake of 13,447 shares — an estimated $1.47M sold.

Silverarc Capital Management first reported a position in CUE in Q4 2022 and held it in 3 quarters. The position peaked at $1.47M in Q2 2023. 75 funds tracked by Wall St. Rank hold CUE as of Q3 2023.

  • Silverarc Capital Management reported no remaining Cue Biopharma position as of Q3 2023 after selling out during the quarter.
  • Silverarc Capital Management sold 13,447 Cue Biopharma shares in Q3 2023, an estimated $1.47M.
  • Silverarc Capital Management first reported a position in Cue Biopharma in Q4 2022 and held it in 3 quarters.
  • Silverarc Capital Management's Cue Biopharma position peaked at $1.47M in Q2 2023.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q3 2023.

Based on Silverarc Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.